Newsroom

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026.Dr. Kale will lead Niagen Bioscience's Global Niagen Research Program, overseeing the Company's worldwide network of academic and clinical research collaborations while helping shape its scie...

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat to Host First Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, August 4, 2026 at 4:30 p.m. Eastern Time...

SAN JOSE, Calif.--(BUSINESS WIRE)--Arlo Technologies, Inc. (NYSE: ARLO), a leading provider of smart home security and monitoring services, today announced that it will hold a conference call with investors and analysts on Thursday, August 6, 2026 at 5:00 p.m. ET (2:00 p.m. PT) to discuss the Company’s second quarter 2026 results. The news release announcing the second quarter 2026 results will be disseminated on August 6, 2026 after the market closes. The toll-free dial-in number for the live...

TORONTO--(BUSINESS WIRE)--La Fiducie de placement immobilier Propriétés de Choix (« Propriétés de Choix ») (TSX : CHP.UN) a annoncé aujourd’hui que les fiduciaires de Propriétés de Choix ont déclaré une distribution en espèces de 0,065 $ par unité de fiducie pour le mois de juillet 2026, ce qui représente 0,78 $ par unité sur une base annualisée, payable le 17 août 2026 aux porteurs de parts dûment inscrits à la clôture des marchés le 31 juillet 2026. À propos de la Fiducie de placement immobil...

TORONTO--(BUSINESS WIRE)--Choice Properties Real Estate Investment Trust (“Choice Properties”) (TSX: CHP.UN) announced today that the trustees of Choice Properties have declared a cash distribution for the month of July, 2026 of $0.065 per trust unit, representing $0.78 per trust unit on an annualized basis, payable on August 17, 2026 to Unitholders of record at the close of business on July 31, 2026. About Choice Properties Real Estate Investment Trust Choice Properties is Canada’s largest rea...

SUGAR LAND, Texas--(BUSINESS WIRE)--CVR Partners, LP (NYSE: UAN), a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products, plans to release its second quarter 2026 earnings results on Wednesday, July 29, after the close of trading on the New York Stock Exchange. The Partnership also will host a teleconference call on Thursday, July 30, at 11 a.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and c...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx’s transplant surveillance offerings in kidney, heart, and lung. Kidney: The policy affirms coverage of AlloSure® Kidney for sur...

CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem, and its integration into routine clinical workflows. AI-assisted review supported...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced the U.S. Food and Drug Administration (FDA) has accepted a Supplemental New Drug Application (sNDA) for Fetroja® (cefiderocol) for the treatment of pediatric patients (at least 26 weeks of gestational age) with hospital-acquired and ventilator-associated bacterial pneumonia (HABP...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentum through the fi...